Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Karenitecin in Recurrent Ovarian or Peritoneal Cancer
NCT00054119Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Jan 2003
- Primary completion
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of karenitecin in ovarian epithelial cancer and primary peritoneal carcinoma (PPC), sponsored by GOG Foundation. Primary endpoints: Frequency of objective response up to 6 years, Duration of objective response up to 6 years and 3 more. Started Jan 2003; status: completed.
02
Drugs
karenitecin
03
Conditions
ovarian epithelial cancerprimary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00054119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054119.